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Photolyzed rhodopsin fR*) catalyzes GTP-binding to cc-transducins (Tee); TwGTPs then activate cGMP 
phosphodiesterase (PDE). PDE activation is arrested by ATP in two ways: (i) initial velocity is suppressed, 
and (ii) PDE velocity rapidly returns to preactivation levels (turnoff). Arrestin (a 48 kDa protein) markedly 
enhances turnoff while not affecting initial velocity. Arrestin in the presence of ATP achieves rapid turnoff 
by directly inhibiting activated PDE, as indicated by its ability to inhibit the direct activation of PDE by 
TcYGMP - PNP (~anylyl-imidodiphosphate). Double reciprocal plots reveal a competition between arres- 
tins and activated transducins for sites on PDE. Blocking R* phosphorylation blocks initial velocity sup- 
pression but does not disturb rapid turnoff. Our data suggest a 2-fold mechanism for PDE deactivation: 
(i) formation of TccGTPs is suppressed by R* phosphorylation, while (ii) activation of PDE by TwGTPs 
is competitively inhibited by arrestins when ATP is present. 
Photoreceptor Phosphodiesterase Transducin 
1, INTRODUCTION 
Bleaching one or more of the 104-lo6 copies of 
rhodopsin on a retinal rod disk membrane (RDM), 
in the presence of GTP, triggers the amplified 
binding of GTP to the a-subunit of the guanine 
nucleotide-binding protein transducin, forming 
Te- GTPs [1,2]. The Ta. GTPs in turn activate 
cGMP phosphodiesterase (PDE) [3]. Addition of 
micromolar concentrations of ATP to the reaction 
mixture causes two changes in the kinetics of flash- 
induced PDE activation [4,5]. First, the initial 
velocity of activation is partially suppressed. 
Second, the time required for activation to turn 
off, to return to its dark velocity, is dramatically 
shortened. 
Abbreviations: R*, photolyzed rhodopsin; Tcu, ar-sub- 
unit of G-protein; cGMP, cyclic guanosine-3’:5 ‘-mono- 
phosphate; CMP-PNP, guanylyl-imidodiphosphate; 
DTT, dithiothreitol; T&, /3, and y-subunits of G- 
protein; A, arrestin, 48 kDa protein, S-antigen; RK, rho- 
dopsin kinase 
Arrestin ~hodopsi~ Phosphorylation 
We previously reported that a 48 kDa protein 
was involved in the ATP-dependent shortening of 
turnoff time in RDM preparations [6,7]. The 48 
kDa protein rapidly ‘arrests’ PDE activation, with 
little or no effect on initial velocity, thus 
prompting us to call the 48 kDa protein arrestin 
[6,7]. Wilden et al. [8] have suggested that arrestin 
achieves turnoff by binding to bleached, phos- 
phorylated rhodopsin, thereby deactivating it, 
while the PDE remains active until its activators 
decay through the hydrolysis of TCX. GTPs to 
Tcr . GDPs. However, GTPase activity of transduc- 
ing is a relatively slow process (20-300 s GTP-‘) 
[9,10] compared to the rapid inactivation of PDE 
observed in the presence of ATP (- 5-l 5 s) [4]. We 
alternatively have proposed that arrestin in the 
presence of ATP directly inhibits the phosphodi- 
esterase to achieve rapid turnoff [6,11]. 
In the present report we demonstrate that ar- 
restin and ATP can significantly inhibit the direct 
activation of PDE by the stable activated form of 
transducin (Tcr * GYP-PNP). We further show 
that arrestin and ATP can turn off flash-induced 
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PDE activation in the presence of the 
nonhydrolyzable GTP analog, GMP-PNP, con- 
trary to expectations of the Wilden et al. model [8]. 
Moreover, we present evidence that the initial 
velocity suppression by ATP results from rhodop- 
sin phosphorylation, while rapid turnoff requires 
arrestin and ATP. We therefore suggest a 2-fold 
mechanism for the ATP-dependent quench: (i) the 
rate of formation of activators, Ta. GTPs, is sup- 
pressed by rhodopsin phosphorylation, while (ii) 
activation of PDE by Tcu. GTPs is competitively 
inhibited by arrestins in the presence of ATP [ 111. 
We have no evidence that rhodopsin phosphoryla- 
tion is required for the arresting action of the 48 
kDa protein on PDE. 
2. MATERIALS AND METHODS 
2.1. Materials 
Fresh bovine eyes were purchased from 
MOPAC, Souderton, PA. [Y-~~P]ATP was ob- 
tained from ICN (2000-5000 Ci/mmol). cGMP, 
Mops and salts were purchased from Sigma; ATP, 
GTP, GMP-PNP and DTT were obtained from 
Boehringer Mannheim. 
2.2. Preparation of rod disk membranes 
RDM were prepared by a standard method [ 121, 
with all procedures carried out under infrared il- 
lumination with the aid of image converters. 
2.3. Purified proteins 
Arrestin was purified from RDM preparations 
by FPLC (Pharmacia) or by low pressure liquid 
chromatography. A hypotonic extract (10 mM 
Tris, 1 mM DTT, pH 7.5) of bovine RDM in the 
dark was applied to a Mono Q anion-exchange col- 
umn, and eluted by a linear salt gradient (O-500 
mM NaCl, 50 mM Tris, 1 mM DTT, pH 7.5). Ar- 
restin eluted at =50% on the salt gradient. Such 
preparations were typically 95% pure and gave 
similar results to those further purified to 
homogeneity on a TSK molecular sieve column. 
Ta-enriched transducin in the long-term ac- 
tivated form (Ta . GMP-PNP) was extracted from 
bleached, washed RDM with GMP-PNP at 
moderate ionic strength according to the pro- 
cedures of Kuhn and Wilden [13]. The purified 
protein contained at least 85% TCY, with T& as the 
major impurity. Ta. GMP-PNP was separated 
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from free nucleotide on a Sephadex G-25 column 
(Pharmacia, PD-10). 
2.4. Rhodopsin phosphorylation 
Rhodopsin phosphorylation was carried out in 
cGMP phosphodiesterase assay mixtures. High 
specific activity [y-32P]ATP was added 15 s prior 
to a light flash calibrated to bleach a desired frac- 
tion of rhodopsin. Reactions were stopped 30 s 
after the flash with an equal volume of electro- 
phoresis buffer containing 4% SDS. The samples 
were electrophoresed in 15% SDS-polyacrylamide 
gels [lo]. After staining and destaining the rhodop- 
sin bands were cut out and digested in Protosol 
(NEN) diluted 1:lO with Ultrafluor (National 
Diagnostics). 
2.5. PDE assay 
PDE velocity was monitored by a real-time pH 
assay using a modification of the method of Lieb- 
man and Evanczuk [ 141. The reaction mixture con- 
tained 4 PM rhodopsin and 5 mM cGMP in Mops 
buffer with additional nucleotides as indicated. 
Samples (0.5 or 0.75 ml) were incubated in a ther- 
mostatically regulated cuvette with magnetic stir- 
rer. A miniature pH electrode (Beetrode, WPI) 
and KCl-filled Ag/AgCl reference were connected 
to a high input impedance electrometer (WPI), 
whose output was fed to a chart recorder and 
stored on FM tape. The reaction was normally 
started by bleaching a calibrated fraction of 
rhodopsin with a photographic strobe (1 ms dura- 
tion). The flash was spectrally shaped by a Wratten 
57 filter and attenuated by calibrated neutral densi- 
ty filters. Experiments were performed in complete 
darkness with the aid of IR image converters. 
2.6. Protein assays 
Protein concentration was determined by Brad- 
ford’s assay [ 151, with bovine serum albumin used 
as a standard. Rhodopsin concentration was deter- 
mined from its absorbance at 502 nm in 1% Am- 
monyx LO. 
3. RESULTS 
3.1. Arrestin shortens turnoff time in RDM 
Fig. 1. demonstrates the essentially exclusive ef- 
fect of arrestin on turnoff time in bovine RDM 
preparations. Flash intensity was increased until 
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Fig.1. Arrestin shortens turnoff time in the presence of 
ATP in RDM, with no effect on initial velocity. 
Stoichiometric proton release with cyclic GMP 
hydrolysis following a flash (hv) of 1 ms duration that 
bleaches a 2.9 x 10m4 fraction of the rhodopsin in the 
presence of 250,uM GTP cofactor (a-c). Curves b and c 
contained 5OOpM ATP added prior to the flash. Curve 
c contained 14 pg purified bovine arrestin prepared ac- 
cording to the procedures outlined in section 2. All 
traces from separate disk membrane samples of the same 
preparation contained 4 pM rhodopsin, 5 mM cyclic 
GMP, 2 mM MgCl2, 100 mM KCI, 1 mM DTT, 20 mM 
Mops, pH 8.0, with T= 25°C and reaction volume = 0.5 
ml. Membranes were from fresh bovine material for this 
and subsequent figures. Linear dark rates have been sub- 
tracted from the records. Rhodopsin phosphorylation 
performed on identical preparations at identical bleach 
levels in the presence of 50pM ATP containing about 30 
pCi of [y-32P]-ATP added 15 s prior to the flash and 
quenched in SDS-containing electrophoresis buffer 30 s 
after flash. The samples were electrophoresed according 
to [lo]; the rhodopsin bands were cut out and counted 
for incorporated “Pi in Triton/toluene scintillation 
fluid. Reaction mixtures that were not bleached under 
similar conditions served as dark controls. Incorporated 
POT/R* in b and c are each means of light-dark dif- 
ferences from 5 light and 5 dark samples. 
the preparation failed to show rapid turnoff in the 
presence of ATP and GTP (curve b). The addition 
of purified bovine arrestin (gel shown in fig.4C) to 
an RDM preparation at this bleach level (2.9 x 
10m4 fraction bleached) significantly shortens turn- 
off time, i.e., the time required for PDE activation 
to return to its dark velocity, while having no ef- 
fect on initial velocity of activation (curve c). To 
determine whether the quenching effects of ar- 
restin are in some way mediated by rhodopsin 
phosphorylation we added high specific activity 
[Y-~~P]ATP to parallel samples of RDM, with and 
without added arrestin, and measured rhodopsin 
phosphorylation at the same bleach level used in 
the pH assay. As shown, the shortening of turnoff 
time by arrestin is achieved without increase in the 
magnitude of rhodopsin phosphorylation. Consis- 
tent with the findings of Pfister et al. [16], we find 
arrestin isolated by anion-exchange chromatog- 
raphy to be devoid of rhodopsin kinase activity. In 
addition, the effect of arrestin is not a nonspecific 
protein effect as lo-fold higher concentrations of 
ovalbumin do not influence turnoff. Similar ef- 
fects of arrestin on turnoff in RDM preparations 
have been recently reported by others [B]. 
3.2. Decay of Tcr. GTP to Ta. GDP is not 
required for deactivation of PDE by arrestin 
Wilden et al. [8] have proposed that the sole ef- 
fect of arrestin is to deactivate R* by binding to 
phosphorylated R*, while PDE ultimately deac- 
tivates through the hydrolysis of T&e GTPs to 
Tcu. GDPs. According to their model, GTP 
hydrolysis is an absolute requirement for turnoff 
of PDE activation, and it should therefore be im- 
possible to turn off a reaction in which a 
nonhydrolyzable GTP analog, GMP-PNP, is 
substituted for GTP. 
Fig.2 shows that flash-induced PDE activation 
in the presence of low concentrations of GMP- 
c 
Fig.2. Arrestins turns off PDE activation in the absence 
of GTP hydrolysis. pH assay of cyclic GMP’hydrolysis 
in the presence of 1OpM GMP-PNP, a nonhydrolyzable 
GTP analog, following a flash that bleached a 
3.0 x 10e5 fraction of the rhodopsin (a-c). Curves b 
and c contained 250pM ATP added prior to the flash. 
Curve c contained 17 pg purified bovine arrestin added 
prior to the light flash. All traces from separate RDM 
samples of the same preparation contained 4 PM 
rhodopsin, 5 mM cyclic GMP, 2 mM MgC12, 100 mM 
KCl, 1 mM DTT, 20 mM Mops, pH 8.0, with T=3O"C 
and reaction volume = 0.75 ml. Linear dark rates have 
been subtracted from the records. 
37 
Volume 207. number 1 FEBS LETTERS October 1986 
PNP (10 PM) can be turned off by arrestin and 
ATP. In curve a, a flash bleach causes essentially 
straight-line activation in the presence of 10 ,uM 
GMP-PNP, as the activators formed by the flash 
(Tu . GMP-PNPs) cannot be hydrolyzed. In curve 
b, 250 PM ATP does little to such activation in 
RDM, but in curve c the addition of 17 pug purified 
bovine arrestin and ATP causes activation to 
return to its dark velocity, thus turning off PDE 
activation. 
The experiment in fig.2 proves that the capping 
of phosphorylated R* by arrestin cannot be its on- 
ly inhibitory action, and is consistent with, but 
alone does not prove, a model in which arrestin in 
the presence of ATP directly inhibits activated 
PDE. The following experiments were designed to 
test this model. 
3.3. Arrestin and A TP directly inhibit activated 
PDE 
PDE was activated directly in dark RDM by ad- 
ding the stable activated form of transducin 
(Ta- GMP-PNP), thus bypassing the normal ac- 
tivation pathway through R*. In fig.3, the addition 
of Tcu. GMP-PNP at time A, to a dark preparation 
containing 50pM ATP, causes PDE activation, in- 
dicated by the upward slope. A subsequent flash 
bleach serves two functions. First, the flash, which 
fails to increase PDE activation above that caused 
by the Ta. GMP-PNP, demonstrates that there is 
no free GMP-PNP in the cuvette, and therefore 
that PDE is not being activated through R* and en- 
Fig.3. Evidence that arrestin in the presence of ATP 
directly inhibits activated PDE. pH record from reaction 
cuvette containing 5 mM cyclic GMP and 50 ,uM ATP 
added prior to time A. At A, 3 pg of the stable PDE ac- 
tivator Tc. GMP-PNP was added to the cuvette. Light 
flash (hv) that bleached a 3.0 x 10e5 fraction of 
rhodopsin failed to increase activation above that caused 
by TCY. GMP-PNP, indicating that PDE is not activated 
through R* and endogenous transducin, but is being ac- 
tivated by exogenously applied Ta.GMP-PNPs. At B, 
the 25 pg purified arrestin added to the cuvette depresses 
PDE velocity by - 80%. Reaction buffer, rhodopsin 
concentration, temperature and volume are the same as 
in fig.2. 
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dogenous transducin. The PDE, then, is being 
directly activated by the exogenously applied ac- 
tivators, Tcu . GMP-PNPs. Second, the flash forms 
R*s required for the activation of arrestin, which 
is added at time B. The addition of arrestin, after 
a slight pH jump, depresses PDE velocity by ap- 
proximately 80%. Arrestin and ATP, therefore, 
directly inhibit activated PDE. Interaction of ar- 
restin with R* is required for its inhibitory action 
on PDE, as arrestin is without effect in the absence 
of R* (not shown). 
3.4. Arrestins and activated transducins compete 
for sites on PDE 
To delineate the mechanism of direct inhibition 
of PDE by arrestin we have repeated experiments 
similar to those shown in fig.3 over a range of 
TLY. GMP-PNP concentrations in the presence and 
absence of arrestin and/or ATP. Gels of the 
purified proteins used, Ta. GMP-PNP and ar- 
restin, are shown in fig.4, panel C, and represen- 
tative pH records shown in panel A. In this series 
of experiments arrestin and/or ATP were added 
prior to the light flash, and PDE velocity measured 
subsequent o the addition of varied concentra- 
tions of Tcr. GMP-PNP, added at time A (fig.4A). 
PDE velocity was measured along the straight-line 
portion of activation subsequent to T~u-GMP-PNP 
addition. Control experiments revealed, as in fig.3, 
that the system was unable to activate through R* 
and endogenous transducin because it lacks free 
guanosine nucleoside triphosphate; PDE is thus 
being directly activated by added Ta. GMP-PNPs. 
Double reciprocal plots of the data are shown in 
fig.4B. The addition of arrestin and ATP (solid 
squares) significantly increases the slope, in- 
dicating inhibition of the direct activation of PDE 
by Tcu . GMP-PNP. ATP in the absence of arrestin 
(open circle) has no effect on PDE velocity, and ar- 
restin in the absence of ATP (solid circle) is also 
without effect. Direct inhibition of activated PDE, 
then, requires arrestin and ATP. 
Linear regression lines through the data points 
intersect on the l/v axis indicating competitive in- 
hibition, i.e., activated transducins and arrestins 
compete for sites on PDE. Wilden et al. [8] failed 
to observe a direct inhibitory effect of arrestin on 
PDE using 3-fold higher concentrations of ac- 
tivators than those at which we observed inhibi- 
tion. This is not surprising, as the definition of 
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Fig.4. Activation of PDE by TCX. PNPs is competitively inhibited by arrestins in the presence of ATP. Representative 
pH records in panel A, double reciprocal piot of data in panel B, gels of purified proteins in panet C. (A) 1Oyg purified 
arrestin and/or 1OOpM ATP added, when indicated, prior to a flash that bleached a 1.6 x lo-’ fraction of rhodopsin. 
Curves: (a) no prior additions, 2,ug Ta. GMP-PNP injected into cuvette at A; (b) 100pM ATP added prior to flash, 
2 pg Ta. CMP-PNP added at A; (c) no prior additions, 1 gg Ta!. GMP-PNP added at A; (d) 10 ,ug arrestin and 100 
,uM ATP added prior to flash, 1 ,ug TCU . GMP-PNP added at A. Reaction buffer, rhodopsin concentration, temperature 
and volume as in fig.2. (B) Arrestin (1Opg) + 1OOpM ATP + Tcu IGMP-PNP ( l ); ‘IQ + GMP-PNP (A); Ta . GMP-PNP 
+ arrestin (10 pg) (0); TCU . GMP-PNP + 100 FM ATP (0). (C7 SDS-PAGE of purified proteins used in this figure, 
panels A and B, and in figs l-3. Left lane, enriched Tcu fGMP-PNP; right lane, purified arrestin prepared as in section 2. 
competitive inhibition predicts, as do our data, 
that such high substrate concentrations should 
overcome the inhibitor, thus explaining their 
negative resuft. 
If we assume Iinear competitive inhibition, we 
can compute an inhibitor constant, Ki, from the 
data, and arrive at a value of 193 nM. This 
translates into approx. 1 arrestin per 20 rhodop- 
sins, a highly selective inhibitory effect comparable 
to inhibition by the y-subunit of PDE on light ac- 
tivation recently reported by Sitaramayya et al. 
1171. 
3.5. Rhodopsin phosphoryiation accounts for the 
initial velocity component of quench 
To explore the role of rhodopsin phosphoryla- 
tion in the ATP-dependent quench, we have 
employed monoclonal anti-rhodopsin antibodies 
against phosphorylation sites on the C-terminus of 
rhodopsin. The monoclonal antibodies employed 
were those prepared and characterized by Molday 
and MacKenzie [ 181. At GTP concentrations 
below the K, for rhodopsin phosphorylation by 
GTP [19] (Fig.5 curves a and b), monoclonal lD4 
Fig.5. Evidence that rhodopsin phosphorylation causes 
initial velocity suppression, but is not required for rapid 
turnoff by arrestin and ATP. Proton release with cyclic 
GMP hydrolysis following a flash that bleached a 
1.5 x lOA5 fraction of rhodopsin in the presence of 50 
pM GTP cofactor (curves a-d). Curves c and d con- 
tained 100 PM ATP added prior to the light flash. 
Curves a and c from RDM samples incubated on ice for 
1 h with 4 FM lD4 monoclonal antibody. Rhodopsin 
phosphoryiation performed as in fig. 1, with PO.+=/R* in 
c and d each representing mean light-dark differences 
from 5 light and 5 dark samples. Reaction buffer, 
rhodopsin concentration, temperature and volume as in 
fig.2. Inset shows initial velocities of activation at in- 
creased gain. Calibration bars pertain to lower pH 
records only. Linear dark rates have been substracted 
from the records. 
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only slightly increases activation. ATP phosphor- 
ylates R* (curve d), as measured at 30 s under iden- 
tical weak bleach conditions to 3.9 POT/R*, and 
rapid turnoff is observed in the RDM preparation. 
Monoclonal lD4 blocks phosphorylation to 0.7 
POT/R*, meaning that on average 30% of the R*s 
have no phosphates on them. Blocking phos- 
phorylation (curve c) increases initial velocity of 
activation; but in the presence of endogenous ar- 
restin, the reaction still turns off. Therefore, 
phosphorylation of R* accounts for the initial 
velocity suppression component of the quench, but 
is not a necessary condition for rapid turnoff of 
PDE by arrestin and ATP. Similar results were 
also obtained with another mono~lonal antibody, 
3A6. A more detailed account of the effects of 
blocking rhodopsin phosphorylation on the 
quench will appear elsewhere. 
4. DISCUSSION 
The data lead us to suggest he following model 
of PDE activation and deactivation: 
Activation 
1. R” + hv 
2. Tao* GDP + GTP 
3. T~u**GTP + PDE’ 
- 
Rz 
- 
Deactivation 
4. A0 f ATP 
R*’ - 
5. R** + nATP 
RK 
6. A* -t- GTP.T~u*.PDE* - 
and 
7. A” i- PDE’ - 
R**, most likely metarhodopsin II [20], formed 
by the bleaching of rhodopsin, catalyzes the ex- 
change of GTP for bound GDP on the a-subunit 
of transducin (1,21. Tcr* 1 GTPs formed by this 
reaction bind to an inactive PDE molecule, PDE’, 
thus activating it [3]. The active diesterase, PDE*, 
hydrolyzes cyclic GMP until it is deactivated by the 
action of A [l I]. R** also catalyzes the formation 
of a deactivating form of arrestin. A*, which com- 
petes for sites occupied by Ta*. GTPs on PDE*, 
deactivating the active diesterases to yield PDE”. 
Similarly, A*s bind to inactive diesterases, PDE”, 
to prevent their activation by Ta*GTPs. Concomi- 
tant with the deactivation of PDE by A*s, R** is 
being phosphorylated by RK and ATP. The 
40 
phosphorylation of R** partially deactivates it 
[8,21], forming R*Pn, which has a significantly 
diminished capacity to catalyze the formation of 
Ta* * GTPs, but which is still competent o catalyze 
the conversion of arrestins to their deactivating 
form, A*s. 
The system would need to recover from deac- 
tivation through a number of processes, some of 
which remain to be worked out. First, the 
Tru* - GTPs hydrolyze to the inactive form of 
transducin, Tao * GDPs [9,10]. Second, R*Pn 
dephosphorylates and passes to an inactive in- 
termediate in the bleaching sequence, R”. Third, 
A* dissociates from PDE, and returns to its inac- 
tive form A” through reactions yet to be deter- 
mined. 
The reactions involved in the R**-catalyzed for- 
mation of deactivating arrestins are currently being 
investigated. We [22], and more recently others 
[23], have shown that arrestin is an adenine 
nucleotide-binding protein, labeling with the 
photoaffinity ligand 8-azido[cu-32P]ATP. More- 
over, partial sequencing of arrestin has revealed 
R** 
Tar* - GTP 
GTP*TLu*.PDE* cG 
5’-GMP i- H+ 
A” 
R*Pn + nADP 
A*‘PDE’ + TLY’GTP 
A* * PDE’ 
homologies with other purine nucleotide-binding 
proteins 1241. Furthermore, arrestin is involved in 
effecting changes in unbound cytosol ATP and 
ADP 16,251. We believe that the deactivation of 
PDE by arrestin is intimately related to the 
presence and form of a bound adenine nucleotide 
on arrestin; further work will reveal the relevant 
binding reactions involved. 
The present model explains features of PDE ac- 
tivation and deactivation which were hitherto 
unexplained. First, the reported weak binding of 
activators, Tcu* .GTPs, to PDE [17] would be 
reasonable if a deactivating molecule, A*, is to 
compete effectively with activator molecules on 
PDE. Second, the model is consistent with 
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previously reported low values for GTPase velocity 
[9,10], as GTP hydrolysis is involved in the slow 
recovery of the system, and not in its rapid deac- 
tivation as proposed by others [Xl. This further im- 
plies that arrestin is functionally most important at 
higher bleach levels at which the GTPase is least 
able to keep up with the amplified production of 
Tm. GTPs. Third, the only requirement for deac- 
tivation of the system by arrestin according to 
Wilden et al. [8] is phosphorylation of R*. 
However, GTP has also been shown to 
phosphorylate R*; yet in the presence of concen- 
trations of GTP alone which exceed its Km for R* 
phosphorylation [ 191 (e.g., fig. 1 a), the system fails 
to show rapid turnoff of PDE activation. We pro- 
pose that the formation of A%, which directly in- 
hibit activated PDEs, is an ATP-specific reaction, 
consistent with the characterization of arrestin as 
an adenine nucleotide-binding protein [22]. 
The present work which demonstrates that ar- 
restin achieves rapid turnoff by directly inhibiting 
the disk complement of PDEs does not, however, 
rule out a role for arrestin in deactivating R* as 
proposed by Wilden et al. [S]. Further work will be 
necessary to resolve the relative contributions of 
the two proposed roles for arrestin in achieving 
quench, thus allowing a theoretical model to be 
formulated which can deal with the kinetic 
subtleties of light-induced PDE activity. 
The hormonally-activated adenylate cyclase 
shares similarities with the cGMP phosphodie- 
sterase in its activation, and turns off through a 
process termed desensitization 1261. It will be in- 
teresting to see whether desensitization involves a 
protein homologous to arrestin, or whether ar- 
restin is a unique evolutionary adaptation to the 
needs of phototransduction. 
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